We are live on
!
Find out more
VVA
Vida Ventures Advisors Portfolio holdings
AUM
$29.4M
1-Year Est. Return
93.58%
This Fund
S&P 500
This Quarter
Est. Return
-10.64%
1 Year Est. Return
+93.58%
3 Year Est. Return
+153.74%
5 Year Est. Return
+14.63%
10 Year Est. Return
–
AUM
$399M
AUM Growth
+$3M
(+0.76%)
Cap. Flow
+$89.9M
Cap. Flow
% of AUM
22.53%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
2
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$92.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OYST
Oyster Point Pharma, Inc. Common Stock
OYST
|
+$2.28M |
| 2 |
Assembly Biosciences
ASMB
|
+$270K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
| $87.3M | 21.9% |
+3,931,818
| New | +$92.4M |
|
|
KRON
2
DELISTED
Kronos Bio
KRON
| $66.2M | 16.61% |
2,765,314
| – | – |
|
|
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $64M | 16.04% |
2,747,433
| – | – |
|
4
Dyne Therapeutics
DYN
$4.24B
| $62.3M | 15.62% |
2,960,046
| – | – |
|
5
Praxis Precision Medicines
PRAX
$8.8B
| $53.7M | 13.47% |
195,955
| – | – |
|
6
Allogene Therapeutics
ALLO
$604M
| $46.9M | 11.76% |
1,798,163
| – | – |
|
|
OYST
7
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $11.3M | 2.84% |
658,468
-120,000
| -15% | -$2.28M |
|
8
Q32 Bio
QTTB
$452M
| $5.6M | 1.41% |
42,825
| – | – |
|
|
9
Assembly Biosciences
ASMB
$513M
| $1.49M | 0.37% |
32,053
-5,447
| -15% | -$270K |
|
Similar funds
NC
PIM
NCPI
TCM
RE
VM
BCA
VCM
Vida Ventures Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, Vida Ventures Advisors held 9 positions worth $399M, up 0.76% from $396M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Vida Ventures Advisors deployed $89.9M of net new capital in Q2 2021, opening 1 new position. Its largest new stake was Centessa Pharmaceuticals: 3,931,818 shares worth $87.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Oyster Point Pharma, Inc. Common Stock, an estimated $2.28M trimmed.
- Vida Ventures Advisors's largest Q2 2021 buy was Centessa Pharmaceuticals: 3,931,818 shares worth $87.3M.
- Vida Ventures Advisors's biggest Q2 2021 reduction was Oyster Point Pharma, Inc. Common Stock, cutting an estimated $2.28M.
- Vida Ventures Advisors's ten largest holdings make up 100% of its $399M portfolio in Q2 2021.
- Vida Ventures Advisors opened 1 new position and closed 0 in Q2 2021.
- Vida Ventures Advisors's portfolio value rose 0.76% quarter-over-quarter to $399M.
Based on Vida Ventures Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.